Nathan E Marshall MD, Robert A
For instance, liraglutide (Victoza), dulaglutide (Trulicity), and subcutaneous semaglutide (Ozempic) have data supporting risk reduction of major adverse cardiovascular events as well as preserving kidney function in patients with T2DM.(2)(3)(4) Another benefit of GLP-1 and GIP/GLP-1 receptor agonists is significant weight loss, specifically seen with liraglutide, semaglutide, and tirzepatide, which are now available as FDA approved products for weight management with the brand names Saxenda, Wegovy, and Zepbond respectively.(5)(6)(7) While these products have great glycemic, weight, and cardiovascular outcomes, the benefits have resulted in some detrimental repercussions
Each purification cycle adds cost, time, and risk of batch failure
Poor-quality peptides may contain contaminants, degradation products, or incorrect doses that compromise both safety and results
Each plan is tailored to individual health needs, lifestyle, and weight loss goals